Qingqing He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Qingqing He has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Tao Chen
Stomatological Hospital of Chongqing Medical University Chongqing Key Laboratory of Oral Diseases and Biomedical Sciences Chongqing Municipal Key Laboratory of Oral Biomedical Engineering of Higher Education Chongqing Medical University Chongqing China
4 shared publications Jinglei Zhan
College of Stomatology, Chongqing Medical University, Chongqing, China; Chongqing Key Laboratory of Oral Diseases, Chongqing, China; Chongqing Municipal Key Laboratory of Oral Biomedical Engineering of Higher Education, Chongqing, China; Chongqing Municipal Health Commission Key Laboratory of Oral Biomedical Engineering, Chongqing, China
2 shared publicationsSi Wang
College of Stomatology, Chongqing Medical University, Chongqing, China; Chongqing Key Laboratory of Oral Diseases, Chongqing, China; Chongqing Municipal Key Laboratory of Oral Biomedical Engineering of Higher Education, Chongqing, China; Chongqing Municipal Health Commission Key Laboratory of Oral Biomedical Engineering, Chongqing, China
2 shared publicationsCongxiu Mao
College of Stomatology, Chongqing Medical University, Chongqing, China; Chongqing Key Laboratory of Oral Diseases, Chongqing, China; Chongqing Municipal Key Laboratory of Oral Biomedical Engineering of Higher Education, Chongqing, China; Chongqing Municipal Health Commission Key Laboratory of Oral Biomedical Engineering, Chongqing, China
1 shared publicationDize Li
Stomatological Hospital of Chongqing Medical University Chongqing Key Laboratory of Oral Diseases and Biomedical Sciences Chongqing Municipal Key Laboratory of Oral Biomedical Engineering of Higher Education Chongqing 401147 P. R. China
1 shared publicationDongqi Fan
College of Stomatology, Chongqing Medical University, Chongqing, China; Chongqing Key Laboratory of Oral Diseases, Chongqing, China; Chongqing Municipal Key Laboratory of Oral Biomedical Engineering of Higher Education, Chongqing, China; Chongqing Municipal Health Commission Key Laboratory of Oral Biomedical Engineering, Chongqing, China
1 shared publication
Latest Publications
- 27 June 2026
- Published by Elsevier in Acta Biomaterialia
- Vol. 219, 491-509
Diabetes alters protein corona to reprogram wear particle–cell interaction
- 27 June 2026
- Published by Elsevier in Acta Biomaterialia
- Vol. 219, 491-509
Diabetes alters protein corona to reprogram wear particle–cell interaction
- Top Cited PapersOpen Access
- 1 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (18) , eaee4401
A robust adhesive microneedle for oral infections therapy via synergistic antibacterial and neutrophil-macrophage axis immunomodulation
Oral infectious diseases are challenging to treat, as conventional therapies struggle to maintain effective drug levels and simultaneously address both infection and immune dysregulation. To address this, we developed a mussel-inspired microneedle patch (PCA@FeCO MN) by incorporating Fe 3 (CO) 12 into a caffeic acid–grafted polyvinyl alcohol network. This design overcomes existing barriers through a dual-adhesion mechanism: a catechol-metal coordination network for strong chemical bonding and an optimized taper geometry for mechanical interlocking in wet oral tissues. Upon near-infrared irradiation, PCA@FeCO MN activates a photothermal-ferroptosis-gas therapy cascade, synergistically eradicating pathogens. Crucially, this strategy also disrupts the inflammation cycle by steering neutrophils toward function activation, timely apoptosis and boosting macrophage efferocytosis. In both rat and beagle dog models of oral infections, PCA@FeCO MN achieved robust tissue adhesion, highly efficient synergistic antibacterial activity, and precise immunomodulation, demonstrating its promising therapeutic potential for future clinical translation.
- 1 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (18) , eaee4401
Top Cited PapersOpen AccessA robust adhesive microneedle for oral infections therapy via synergistic antibacterial and neutrophil-macrophage axis immunomodulation
Oral infectious diseases are challenging to treat, as conventional therapies struggle to maintain effective drug levels and simultaneously address both infection and immune dysregulation. To address this, we developed a mussel-inspired microneedle patch (PCA@FeCO MN) by incorporating Fe 3 (CO) 12 into a caffeic acid–grafted polyvinyl alcohol network. This design overcomes existing barriers through a dual-adhesion mechanism: a catechol-metal coordination network for strong chemical bonding and an optimized taper geometry for mechanical interlocking in wet oral tissues. Upon near-infrared irradiation, PCA@FeCO MN activates a photothermal-ferroptosis-gas therapy cascade, synergistically eradicating pathogens. Crucially, this strategy also disrupts the inflammation cycle by steering neutrophils toward function activation, timely apoptosis and boosting macrophage efferocytosis. In both rat and beagle dog models of oral infections, PCA@FeCO MN achieved robust tissue adhesion, highly efficient synergistic antibacterial activity, and precise immunomodulation, demonstrating its promising therapeutic potential for future clinical translation.
- 28 March 2026
- Published by SAGE Publications in Journal of Dental Research
- Vol. 105 (13) , 1791-1802
Acsl1-Mediated Fatty Acid Synthesis Impairs Osseointegration in Type 1 Diabetes
Diabetes mellitus is considered a relative contraindication to oral implant therapy, as hyperglycemia frequently precipitates vascular and osseous pathologies. Although clinicians routinely prioritize glycemic control before initiating implant-related treatment plans, diabetic patients often exhibit impaired osseointegration. However, the specific mechanisms remain to be elucidated. Emerging evidence suggests that this refractory bone loss is mediated by trained immunity, a process in which innate immune cells retain an epigenetic memory of prior inflammatory stimuli and mount an exaggerated response upon secondary challenge such as the invasive implantation process or inflammatory insult. Here, integrating RNA-seq, metabolomics, and transposase-accessible chromatin using sequencing analyses, we demonstrate that stringent glycemic control in type 1 diabetes fails to normalize the fatty acid biosynthetic process, which remains persistently activated and potentiates macrophage-mediated inflammation and osteoclastogenesis when experiencing the secondary stimuli. Mechanistically, prior hyperglycemic exposure enhances chromatin accessibility while sustaining Acsl1 transcription by H3K4me1 epigenetic modification at the Acsl1 locus in macrophages. This epigenetic imprint augments fatty acid anabolism, amplifies proinflammatory cytokine production, and accelerates osteoclastic differentiation, ultimately compromising osseous repair. Collectively, our findings reveal that diabetes-induced H3K4me1 modification at Acsl1 drives metabolic reprogramming underpinning trained immunity and consequent bone damage. Targeting H3K4me1 or Acsl1 therefore represents a promising therapeutic strategy to improve implant osseointegration and skeletal regeneration in diabetic patients.
- 28 March 2026
- Published by SAGE Publications in Journal of Dental Research
- Vol. 105 (13) , 1791-1802
Acsl1-Mediated Fatty Acid Synthesis Impairs Osseointegration in Type 1 Diabetes
Diabetes mellitus is considered a relative contraindication to oral implant therapy, as hyperglycemia frequently precipitates vascular and osseous pathologies. Although clinicians routinely prioritize glycemic control before initiating implant-related treatment plans, diabetic patients often exhibit impaired osseointegration. However, the specific mechanisms remain to be elucidated. Emerging evidence suggests that this refractory bone loss is mediated by trained immunity, a process in which innate immune cells retain an epigenetic memory of prior inflammatory stimuli and mount an exaggerated response upon secondary challenge such as the invasive implantation process or inflammatory insult. Here, integrating RNA-seq, metabolomics, and transposase-accessible chromatin using sequencing analyses, we demonstrate that stringent glycemic control in type 1 diabetes fails to normalize the fatty acid biosynthetic process, which remains persistently activated and potentiates macrophage-mediated inflammation and osteoclastogenesis when experiencing the secondary stimuli. Mechanistically, prior hyperglycemic exposure enhances chromatin accessibility while sustaining Acsl1 transcription by H3K4me1 epigenetic modification at the Acsl1 locus in macrophages. This epigenetic imprint augments fatty acid anabolism, amplifies proinflammatory cytokine production, and accelerates osteoclastic differentiation, ultimately compromising osseous repair. Collectively, our findings reveal that diabetes-induced H3K4me1 modification at Acsl1 drives metabolic reprogramming underpinning trained immunity and consequent bone damage. Targeting H3K4me1 or Acsl1 therefore represents a promising therapeutic strategy to improve implant osseointegration and skeletal regeneration in diabetic patients.
- 27 May 2021
- Published by Wiley in Advanced Functional Materials
- Vol. 31 (31) , 2101611
Safeguarding Osteointegration in Diabetic Patients: A Potent “Chain Armor” Coating for Scavenging ROS and Macrophage Reprogramming in a Microenvironment‐Responsive Manner
Risk of implant failure increases profoundly in patients with pre‐existing conditions (e.g., diabetes). Current therapies adopt a one‐sided focus on the direct antibacterial properties of biomaterials and osteogenesis stimulation. However, in this study it is demonstrated that a “chain armor” structure (Ce‐TA) that mainly targets the regulation of the local pathological microenvironment, provides a novel solution to scavenge reactive oxygen species (ROS) by simulating superoxide dismutase and catalase and significantly improving osteointegration under diabetic conditions. Ce‐TA based on a metal phenolic network biological functional interface is successfully constructed. Ce‐TA, an ultrathin armor structure, is biocompatible and facile. Through in vitro assays it is demonstrated that Ce‐TA reshapes the diabetic microenvironment into a regenerative one in a microenvironment‐responsive manner, where Ce‐TA regulates hypoxia‐inducible factor 1α (HIF‐1α) activity by reducing the level of mitochondrial ROS, and effectively alleviates mitochondrial dysfunction and reprogrammes macrophages to a pro‐healing state. Furthermore, it is confirmed that Ce‐TA shows excellent therapeutic effects on the reducing postoperative infection and enhances osteointegration of intra‐osseous implants in diabetic rat models. The proposed strategy opens up a promising opportunity for repurposing metals with intrinsic enzyme‐like activity for the goal of enhancing the osteointegration of devices with orthopedic and dental applications among diabetic patients.
- 27 May 2021
- Published by Wiley in Advanced Functional Materials
- Vol. 31 (31) , 2101611
Safeguarding Osteointegration in Diabetic Patients: A Potent “Chain Armor” Coating for Scavenging ROS and Macrophage Reprogramming in a Microenvironment‐Responsive Manner
Risk of implant failure increases profoundly in patients with pre‐existing conditions (e.g., diabetes). Current therapies adopt a one‐sided focus on the direct antibacterial properties of biomaterials and osteogenesis stimulation. However, in this study it is demonstrated that a “chain armor” structure (Ce‐TA) that mainly targets the regulation of the local pathological microenvironment, provides a novel solution to scavenge reactive oxygen species (ROS) by simulating superoxide dismutase and catalase and significantly improving osteointegration under diabetic conditions. Ce‐TA based on a metal phenolic network biological functional interface is successfully constructed. Ce‐TA, an ultrathin armor structure, is biocompatible and facile. Through in vitro assays it is demonstrated that Ce‐TA reshapes the diabetic microenvironment into a regenerative one in a microenvironment‐responsive manner, where Ce‐TA regulates hypoxia‐inducible factor 1α (HIF‐1α) activity by reducing the level of mitochondrial ROS, and effectively alleviates mitochondrial dysfunction and reprogrammes macrophages to a pro‐healing state. Furthermore, it is confirmed that Ce‐TA shows excellent therapeutic effects on the reducing postoperative infection and enhances osteointegration of intra‐osseous implants in diabetic rat models. The proposed strategy opens up a promising opportunity for repurposing metals with intrinsic enzyme‐like activity for the goal of enhancing the osteointegration of devices with orthopedic and dental applications among diabetic patients.